Best Antibiotic for Chest Infection Following Rib Fractures
For a chest infection following rib fractures in a hospitalized patient, use piperacillin-tazobactam 4.5g IV every 6 hours, cefepime 2g IV every 8 hours, or levofloxacin 750mg IV daily as first-line empiric therapy if the patient has no risk factors for MRSA and is not at high risk of mortality.
Clinical Context and Risk Stratification
Rib fractures create a unique scenario where chest infection can develop through two mechanisms: (1) hospital-acquired pneumonia (HAP) from hypoventilation and poor secretion clearance, or (2) post-traumatic empyema from chest tube placement or direct contamination. The key to antibiotic selection is determining whether this is a hospital-acquired infection versus a community-acquired infection at presentation.
If This is Hospital-Acquired Pneumonia (developed after admission):
The 2016 IDSA/ATS guidelines provide clear algorithmic guidance 1:
Step 1: Assess mortality risk
- High risk = need for ventilatory support OR septic shock
- If neither present = NOT high risk
Step 2: Assess MRSA risk factors
- IV antibiotics in prior 90 days
- Unit MRSA prevalence >20% or unknown
- Prior MRSA colonization/infection
Step 3: Select regimen based on risk stratification:
Low mortality risk + No MRSA risk factors:
Choose ONE of the following 1:
- Piperacillin-tazobactam 4.5g IV q6h
- Cefepime 2g IV q8h
- Levofloxacin 750mg IV daily
- Imipenem 500mg IV q6h
- Meropenem 1g IV q8h
Low mortality risk + MRSA risk factors present:
Same options as above PLUS add 1:
- Vancomycin 15mg/kg IV q8-12h (target trough 15-20 mg/mL)
- OR Linezolid 600mg IV q12h
High mortality risk OR recent IV antibiotics:
Use TWO agents from different classes (avoid two β-lactams) PLUS MRSA coverage 1
If This is Post-Traumatic Empyema:
The 2025 WSES-AAST thoracic trauma guidelines specify different coverage 2:
For hospital-acquired/post-procedural empyema (which applies to rib fractures with chest tubes):
- Antibiotics must cover MRSA and Pseudomonas aeruginosa
- Continue anaerobic coverage empirically even if cultures negative
- No role for intrapleural antibiotics
Practical regimen: Piperacillin-tazobactam 4.5g IV q6h (covers Pseudomonas and anaerobes) PLUS vancomycin or linezolid (covers MRSA)
Key Clinical Pitfalls
Common mistake #1: Using prophylactic antibiotics for rib fractures alone without infection. The evidence supports prophylaxis only for penetrating chest trauma with chest tubes 3, 4, 5, not for closed rib fractures. If your patient has developed an actual infection, this is treatment, not prophylaxis.
Common mistake #2: Assuming all chest infections after rib fractures are pneumonia. Post-traumatic empyema has a 32.8% cumulative incidence in trauma patients 2 and requires broader coverage including anti-pseudomonal and anti-MRSA therapy.
Common mistake #3: Inadequate MRSA coverage in high-risk patients. If the patient received IV antibiotics in the prior 90 days or MRSA prevalence is unknown, empiric MRSA coverage is essential 1.
Oral Therapy Transition
Since your patient can take oral medications, once clinically stable and cultures guide therapy, consider transitioning to:
- Levofloxacin 750mg PO daily (if fluoroquinolone-susceptible organism)
- Linezolid 600mg PO q12h (if MRSA and oral therapy needed)
Duration of Therapy
- HAP without complications: 7 days typically sufficient
- Empyema: Continue until clinical resolution, chest tube removed, and source controlled (often 2-3 weeks minimum)
Algorithm Summary
- Determine infection type: HAP vs empyema (imaging + pleural fluid analysis if effusion present)
- Assess mortality risk: Ventilatory support needed? Septic shock?
- Assess MRSA risk: Recent IV antibiotics? Unknown local prevalence?
- Select empiric regimen per above algorithm
- Obtain cultures before starting antibiotics when possible
- De-escalate based on culture results and clinical response at 48-72 hours
The evidence strongly supports this algorithmic approach, with the 2016 IDSA/ATS guidelines providing the most comprehensive framework 1, supplemented by trauma-specific guidance for empyema management 2.